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Foodallergiesarecausedbyimmunologicalreactionsinindividualssensitizedtonormalproteincomponentsoffoods.Forany
givensensitizedindividual,theseverityofareactionisgenerallyassumedtobeproportionaltothedoseofallergenicprotein.
There is substantial clinical evidence that “threshold” doses exist for the elicitation of an allergic reaction; however, the
threshold (i.e., lowest dose that elicits a reaction) varies substantially across the sensitized population. Current approaches
to protecting sensitized individuals from exposure to food allergens are highly qualitative (i.e., they rely on food avoidance).
The Key Events Dose-Response Framework is an analytical approach for reﬁning understanding of the biological basis
of the dose-response. Application of this approach to food allergy provides a foundation for a more rigorous quantitative
understanding of variability in allergic response. This study reviews the allergic disease process and the current approaches
to identifying thresholds for food allergens. The pathway of key biological events occurring between food intake and allergic
response is considered, along with factors that may determine the nature and severity of response to food allergens. Data
needs, as well as implications for identifying thresholds, and for characterizing variability in thresholds, are also discussed.
Keywords Low dose dose-response, food allergy, thresholds, minimal eliciting dose, Key Events Dose-Response
Framework
INTRODUCTION
Food allergies are caused by immunological responses to
speciﬁc protein components of foods. True food allergies are
distinct from other forms of adverse reactions that are more
appropriately termed food intolerances; these do not involve
immunological mechanisms. On the basis of the total weight
of evidence, the Health Council of The Netherlands estimates
the prevalence of food allergies generally in the range of 1–
2% for adults and 1–3% for children (Health Council of the
Netherlands, 2007). Other studieshave foundthat foodallergies
may affect up to 4% of adults and 6–8% of children (Nowak-
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Wegrzyn and Sampson, 2006; Venter et al., 2006). Food allergic
reactions are estimated to result in approximately 30,000 emer-
gency room visits and 150 deaths each year in the United States
alone (Sampson, 2003).
Worldwide, over 150 different foods have been reported to
causefood-allergicreactions(Heﬂeetal.,1996);however,itap-
pears that a relatively limited number of foods are responsible
for most instances of food allergy reactions. The most common
allergenic foods in the U.S. are peanuts, tree nuts (e.g. wal-
nuts, almonds), soy, egg, milk, wheat, ﬁsh (e.g. salmon, cod),
and crustacean shellﬁsh (e.g. shrimp, crab, lobster) as estab-
lished by the Food Allergen Labeling and Consumer Protection
Act of 2004. In Canada, the list of commonly allergenic foods
also includes molluscan shellﬁsh (e.g. clam, oyster, squid) and
sesame seed. In the European Union, sesame seed, mustard,
celery, molluscan shellﬁsh, and lupine are also considered to be
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Table 1 Symptoms of IgE-Mediated Food Allergies
Gastrointestinal Symptoms Respiratory Symptoms
Nausea Rhinitis
Vomiting Asthma
Diarrhea
Abdominal Pain
Colic
Other Symptoms
Laryngeal Edema
Anaphylactic Shock
Hypotension
Cardiac Arrhythmia
Cutaneous Symptoms
Urticaria
Eczema or Atopic Dermatitis
Angioedema
Pruritis
common allergenic foods. Other foods are of concern in other
parts of the world probably due to different dietary habits. An
example would be buckwheat in Japan and Korea, which may
be related to the frequent consumption of buckwheat noodles in
those countries.
Food allergies can manifest in a wide variety of signs and
symptoms (Taylor and Heﬂe, 2001), ranging from subjective
symptoms, such as mild itching or nausea, to severe signs, in-
cluding extensive urticaria or anaphylactic shock (Table 1). For
any given individual patient, the severity of a reaction is gen-
erally assumed to be proportional to the level of intake of the
offending food (i.e., level of exposure to protein allergens) and
that individual’s degree of sensitization. This assumption has
not been rigorously tested in part due to ethical restrictions. In-
dividual sensitivity may also be affected by a number of factors
including stress, exercise, other medical conditions, and medi-
cations, although this is well documented only for exercise.
The allergic reaction to food allergens is generally believed
to be “thresholded.” Clinical data indicate that the threshold
dose level, sometimes referred to as the Minimal Eliciting Dose
(MED),canvaryfrompersontoperson,andcanalsovarywithin
an individual over time. A wide range of individual threshold
doses exists across the food-allergic population (Taylor and
Hourihane, 2008). Whether this range represents a continu-
ous distribution of sensitivity within the allergic population or
whether discrete highly sensitive subpopulations exist, is not
known.
Because of the potentially severe consequences of an aller-
gicfoodreaction,sensitizedindividualsareadvisedtoavoidany
exposure, no matter how small, of the allergenic food. More-
over, extensive efforts are taken by the food industry to avoid
inadvertent introduction of food allergens into processed foods.
Meanwhile, there is solid evidence that suggests a small amount
of exposure to allergens does not pose a risk in every sensitized
individual. But which individuals are at risk, and at what dose
levels? Identifying actual threshold levels for speciﬁc individ-
uals and identifying protective thresholds for a population of
sensitized individuals is a major public health challenge.
Often,theestablishment of“safe”doses isapproached rather
pragmatically with dose-response experiments in laboratory
animals or even humans. However, a more mechanistic ap-
proachmayofferanalternative.TheKeyEventsDose-Response
Framework is an analytical approach for systematically evalu-
ating key biological events that underlie a given dose-response
relationship. The goal of this framework is to deepen under-
standing of the dose-response relationship and thereby improve
the scientiﬁc basis for identifying safe levels of exposure or
intake. This Key Events approach is intended to complement
currently available standard approaches to studying low dose
dose-response for food allergens and other agents in foods, such
as nutrients, additives, and environmental contaminants and is
detailed in the introductory paper for this series (Julien et al.,
2009).
Asdescribedinthatintroductorypaper,theKeyEventsDose-
Response Framework is based on the premise that for any given
bioactive agent, chemical, allergen, pathogen, etc., there are
multiple “key events” along the biological pathway from ini-
tial intake to the ultimate effect of concern. Moreover, a va-
riety of physiological mechanisms, for example homeostatic
feedback mechanisms, immune response mechanisms, repair
mechanisms, may operate at these events to maintain a normal
biological environment. Various other factors such as life stage,
disease state, genetic makeup, etc. can modify the effectiveness
of these mechanisms, and thus also play a role in determining
outcome.Soateachbiologicaleventbetweeninitialdose/intake
and the ultimate effect of concern, multiple factors combine to
determine the overall dose-response relationship. An analysis
of dose-response at individual key events should provide in-
sight and help to better characterize the overall dose-response
relationship.
The remainder of this paper will review the allergic disease
process as well as current approaches to identifying thresholds
for food allergens. Then, application of the Key Events analyt-
ical approach will be discussed along with research needs and
potential implications for public health standard setting.
BACKGROUND
Overview of the Allergic Disease Process
The manifestation of a food allergy is a complex two-step
process (Taylor and Heﬂe, 2001). The ﬁrst step is referred to as
“sensitization.” Sensitization requires exposure to protein aller-
gens inthefoodalthough oralexposure isnottheonlyroutethat
can induce sensitization. Oral exposure to dietary proteins usu-
ally results in oral tolerance (Strobel and Mowat, 2006), which
is the normal homeostatic response. Food allergy can be viewed
as a breakdown in, or non- or underdevelopment of, oral toler-
ance in an individual. The reasons for this breakdown or non- or
underdevelopment are unclear because even food-allergic indi-
vidualsarereactivetoonlyoneorafewofthemanyhundredsof
thousands of proteins that are ingested with the diet. Moreover,
there is a wide range of responses to a particular allergenic food
(e.g., individual threshold doses for peanut can range from 0.5
up to 8000–10,000 mg of peanut (0.125 to 2000–2500 mg of
total peanut protein) (Taylor et al., 2009)) and this may partiallyKEY-EVENTS DOSE REPSONSE FRAMEWORK 731
be due to individual differences in the degree of oral toler-
ance. Thus, sensitization can perhaps be viewed as a spectrum
ranging from complete oral tolerance to various degrees of non-
tolerance as evidenced by ever decreasing individual threshold
doses.
With some allergenic foods (e.g. milk) the allergic state may
spontaneously revert over time. Infants who develop milk al-
lergy may outgrow that allergy over a matter of months or years
and ultimately become fully tolerant of milk ingestion (Bishop
etal.,1990).Someindividuals,however,havepersistentmilkal-
lergy(Skripak et al.,2007). Themechanisms involved inthede-
layed development of tolerance to a speciﬁc food, such as milk,
are not known. Recently, clinical research has demonstrated
that oral tolerance to peanut can be induced by intentional oral
administration of very low, slowly escalating doses of peanut
(Jones et al., 2009). And, the likelihood of developing delayed
oral tolerance to certain foods such as peanuts is considerably
less than for other foods such as milk (Bock, 1986). The biolog-
ical mechanisms associated with these observed differences are
poorly understood.
Both sensitization and oral tolerance to foods are most likely
to occur in infancy as new foods are introduced into the diet.
However, with respect to sensitization, it is possible to become
sensitized to a food at any age. With some food allergies like
thosetocrustaceanshellﬁsh,sensitizationtendstooccuratolder
ages perhaps because dietary exposure tends to increase with
age. However, no clinical evidence exists to indicate that a size-
able number of new food allergies develop in older individuals
so oral tolerance remains as the most typical response to the
introduction of new foods in older individuals. Other events,
including intestinal infections or inﬂuenza, may trigger or facil-
itate sensitization and thus development of a food allergy. The
role of infections in enhancing the likelihood of allergic sensiti-
zation is better understood with respiratory infections and aller-
gens. While avoidance of commonly allergenic foods has been
advocated to prevent sensitization, evidence indicates that this
approach has limited effectiveness (Zeiger and Heller, 1995).
In fact, some evidence suggests that the early introduction of
allergenic foods into the diet of infants may actually increase
the development of tolerance (Lack, 2008).
The second step in the allergic disease process is elicitation.
Elicitation of an allergic reaction occurs when a sensitized in-
dividual is re-exposed to a food allergen under conditions that
allow sufﬁcient binding to occur between the allergen or its
fragments and allergen-speciﬁc IgE antibodies bound to mast
cellsandbasophilssuchthatphysiologicallyactivemediatorsof
allergicdiseasearereleasedfromthesemastcellsandbasophils.
There are several potential complications in this
sensitization-elicitation process. First, there is the problem of
cross-reactivity, whereby sensitization to a given food allergen
can occur via exposure to a non-food substance or via expo-
sure to a different food product. For example, sensitization
to an allergen via the respiratory route or via skin exposure
can convey cross-sensitization to foods that contain proteins
with sufﬁciently similar IgE-reactive epitopes (Aalberse et al.,
2001). Well-known examples include cross-sensitization to ap-
ples and hazelnuts with birch pollen, cross-sensitization to cel-
ery and carrots with mugwort pollen, and cross-sensitization
to kiwi and banana with latex allergens. Many times, aller-
gic reactions to these foods are very mild, for example the
oral allergy syndrome (itching, angioedema, or urticaria occur-
ring around the mouth). Some sensitized individuals may react
to respiratory exposure but not to oral intake of an allergenic
food; an example is “baker’s asthma” upon occupational expo-
sure to components of dust in bakeries occurring in individuals
who can safely consume bakery products (Moneret-Vautrin and
Morisset, 2005).
Sensitization to one particular food allergen may also con-
vey cross-reactivity to related foods. Again, this relates to the
existence of similar proteins with similar IgE epitopes in re-
lated species. For example, tropomyosin is a well-described
allergen in crustacean shellﬁsh, and individuals sensitized to
shrimp tropomyosin are likely to also react to crab and lob-
ster (Lehrer et al., 2003). But, such cross-reactions do not
universally occur. The human diet contains more than 300
edible species of legumes including two commonly aller-
genic ones, peanuts and soybeans. However, cross-reactions
do not often occur in peanut- or soy-allergic individuals to
other legumes, although they are occasionally encountered
(Bernhisel-Broadbent and Sampson, 1989). Furthermore, re-
cent studies of certain food allergies suggest that IgE anti-
bodies speciﬁc to carbohydrate moieties on glycoproteins may
be involved in cross sensitization. However, in this particular
case, the cross-reactivity is of questionable clinical signiﬁcance
(van Ree, 2004).
Speciﬁc IgE antibodies may also recognize more than one
protein (Taylor and Lehrer, 1996). Further, allergic individu-
als may produce several speciﬁc IgEs that recognize different
proteins from a particular food, although it is not clear if all
of these IgEs are of equivalent clinical signiﬁcance. The spec-
trum of targeted proteins varies between individuals allergic to
a given food, although some proteins from a particular food are
more commonly targeted than others. The speciﬁc epitopes that
are recognized on a given food protein may also vary across in-
dividuals, although some epitopes are more commonly targeted
than others.
Another complication is the fact that sensitization does not
invariably correlate with the development of clinically signiﬁ-
cant food allergy. Some individuals will have food-speciﬁc IgE
antibodies in their serum and tissues but will not experience al-
lergic reactions upon exposure to that food. There are numerous
potential reasons for this lack of reaction, including inadequate
binding of the allergen to the IgE antibody, insufﬁcient dose,
and digestive instability of the allergen.
The multiple complications in the sensitization-elicitation
process, i.e., cross-reactivity, development of antibodies to mul-
tiple antigens in a given food, development of IgE antibodies
withoutsubsequentallergicreaction,hindertheidentiﬁcationof
the mechanisms underlying food allergy. In turn, this compli-
cates the study of low-dose dose-response.732 S. L. TAYLOR ET AL.
Current Approaches to Characterizing Low Dose
Dose-Response
Asexplainedabove,therearetwodistinctprocessesinvolved
in the development of a food allergy, sensitization and elicita-
tion. Likewise, there are presumably two distinct dose-response
relationships.Boththesensitizationandtheelicitationprocesses
are probably thresholded although this has not been rigorously
demonstrated for sensitization.
A great deal of data regarding the food-allergic response
has been gathered in human studies. Unlike studies of other
substances in foods (e.g., pesticides, additives), data on food
allergens can be obtained via human oral challenge trials. But
the study of sensitization in human subjects is complicated by
thefactthatmostallergenicfoodsarenormalcomponentsofthe
human diet; these foods are likely to be consumed in reasonably
large quantities until allergic sensitization leads to elicitation of
anallergicresponse.Thus,many,butnotall,individualswhobe-
comesensitizedandallergictoaspeciﬁcfoodhavebeenexposed
to rather large, but ill-deﬁned, amounts of the allergenic foods
or to cross-reacting foods or other materials such as pollens or
latex.Incontrasttosensitization,thedose-responserelationship
for elicitation can be explored using sensitized human subjects.
In fact, virtually all data on threshold doses for elicitation
have been obtained from human clinical studies. Predictive an-
imal models, able to distinguish potent allergens from nonal-
lergenic or weakly-allergenic proteins on a consistent basis,
do not exist for food allergies, either for sensitization or elic-
itation (Goodman et al., 2008; Knippels et al., 2004; Nelde
et al., 2001). Like humans, most animals are prone to be-
come orally tolerant to dietary proteins, thus sensitization usu-
ally requires provocation of the immune system by unusual
routes of exposure (e.g. intraperitoneal) and the use of adju-
vants. So far, none of the existing animal models is able to
discriminate between proteins with distinct allergenic potential
for humans. Further research on animal models is warranted;
however, presently, animal models cannot provide quantita-
tive data related to thresholds for either human sensitization or
elicitation.
Published human data do exist on threshold doses for elici-
tation of allergic reactions and can be found from several types
of studies including clinical trials aimed at deﬁning biologi-
cal thresholds, immunotherapy trials where a baseline thresh-
old dose must be determined to assess the effectiveness of the
therapeutic approach, and low dose diagnostic double-blind,
placebo-controlled food challenges (DBPCFCs). Of these, the
most useful studies are DBPCFCs which are designed to be ob-
jective and unbiased (Taylor and Hourihane, 2008). DBPCFCs
provide data on individual thresholds for humans allergic to
speciﬁc foods. A very wide range of individual thresholds is
known to exist, e.g. from 0.5 to 10,000 mg for peanut (Taylor
etal.,2009;TaylorandHourihane,2008;Bindslev-Jensenetal.,
2002). For most foods, however, the distribution of individual
thresholds within the sensitive population has not yet been well
established.
While the acquisition of human data on individual thresh-
old doses offers a practical approach to determining thresholds
for populations of food-allergic individuals, the existing clinical
data may not be fully satisfactory for several reasons. While
DBPCFCs have been widely used for the diagnosis of food
allergies, diagnostic DBPCFCs are often not useful for the iden-
tiﬁcationofindividualthresholdsorcharacterizationoflowdose
dose-response. The doses of the allergenic foods used for the
diagnostic process are often quite high (>250 mg). More than
20% of patients in diagnostic DBPCFCs react to the ﬁrst dose
whichpreventsidentiﬁcationofNOAELs(Sichereretal.,2000).
In theory, it should be possible to combine data from multiple
DBPCFC studies to generate a dose-response curve. But, his-
torically, there has been no standard protocol used with regard
to the speciﬁc form of the food, the amount and the speciﬁc
type of protein in the food, the dose range for the challenges,
the timing of the challenges, the recording of symptoms (es-
pecially subjective responses), and subject selection. Recently,
however, a consensus clinical protocol was published for con-
ductingDBPCFCstudiestowardsidentifyingthresholds(Taylor
et al., 2004).
Theselectionofsubjectsforclinicaltrials,inparticular,raises
questions with regard to the applicability of study ﬁndings to
the broader food-allergic population. Some clinics may exclude
subjectsfromlowdosechallengetrialsifthesubjecthasahistory
ofseverereactions,eventhoughdatadonotexisttoconcludethat
severe responders are necessarily more likely to be reactive at
low doses. Additionally, most low dose clinical challenges have
been conducted at referral centers where the tendency may exist
to select patients who may be more sensitive than the overall
food-allergic population. It is not known whether, and to what
extent, these phenomena affect available threshold information
and how these phenomena balance against each other.
In addition to the difﬁculties noted above (diverse protocols,
subject selection, and lack of multiple doses in diagnostic stud-
ies), other factors may affect the threshold values observed in a
clinical trial, including concomitant exercise or other stresses,
other diseases, age, the presence of seasonal pollen allergies,
pharmaceutical treatments, etc. In addition, as noted, oral tol-
erance to food allergens can develop over time, such that indi-
vidual thresholds change. For example, many infants“outgrow”
their allergies to certain allergenic foods (especially milk, egg,
soy, and wheat) (Bock, 1986). In other words, their individual
thresholds increase over time until they become tolerant of the
amounts typically contained in the human diet. All these poten-
tiallyconfoundingfactorscanbecontrolledinclinicalthreshold
trials, although it is difﬁcult to control for the development of
tolerance over time.
Thus, the assessment of thresholds for food-allergic reac-
tions using human clinical data, while quite promising, remains
fraught with obstacles. Currently, some data exist on threshold
doses for several commonly allergenic foods, including peanut,
milk,andeggs(TaylorandHourihane,2008).Lessdataexistfor
treenuts,ﬁsh,crustaceanshellﬁsh,wheat,soybeans,lupine,and
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a larger number of subjects for most allergenic foods. The use
oftheconsensus,low-doseclinicalthresholdprotocol(Tayloret
al., 2004) by multiple clinics would facilitate the combined use
of data from those clinics. However, approaches are also needed
for utilizing clinical data from the multiple clinics that use di-
verse protocols. Attention needs to be paid to patient selection
criteria for clinical trials to assure that the subjects are indeed
representative of the overall population of individuals allergic
to a certain food.
Current Approaches to Setting Regulatory Standards for
Public Health
At this time, there is no cure for a food allergy, and no
generally recognized “safe” levels of allergens. Thus, current
regulatory approaches for food allergens are purely qualitative,
i.e., a product either does, or does not contain allergens, and
public health strategies therefore focus on preventing the elici-
tationofallergicreactionsinsensitizedindividuals.Thisisdone
by providing such individuals with notice, via food product la-
bels, of the presence of allergenic foods. This strategy requires
allergic individuals to avoid intake of food with the potential to
contain even minute amounts of an allergen.
The strategy of relying on product labels and strict food
avoidance by allergic consumers poses difﬁculties for allergic
individuals. In addition to the inconvenience, strict food avoid-
ance can deprive allergic individuals of foods with high nutri-
tional value. Food products are labeled as containing allergenic
foods even in cases where rather small amounts are present.
Because oftheuncertaintyregarding thresholddosesandthere-
sulting qualitative regulatory strategy, food manufacturers tend
to declare the presence of trace amounts, or even possible trace
amounts on the label. Precautionary labeling (e.g. “may con-
tain”) is in widespread use as a result of this approach. Food-
allergic consumers are often confused about the need to avoid
ingredients derived from allergenic sources, especially in cases
where those ingredients contain very low concentrations of the
allergenic proteins; examples would include peanut oil, ﬁsh oil,
soybean lecithin, lactose, and many others. All of these factors
tend to further restrict the diets of food-allergic consumers.
The regulatory uncertainty about thresholds is also problem-
atic for the food industry. For industry, the current regulatory
strategy can lead to the need to implement expensive allergen
control strategies, sometimes requiring strict segregation of ma-
chinery and/or extra steps in food processing and packaging,
to prevent inadvertent contamination of unlabeled foods with
minute amounts of allergenic protein.
Regulatoryconsensusdoesnotexistinanycountryorregula-
tory jurisdiction regarding how to determine population thresh-
olds for any allergenic food. Several factors may contribute
to this situation. First, consensus does not exist regarding ap-
proaches for evaluating existing human data, although the U.S.
Food & Drug Administration has indicated that they favor the
use of risk assessment approaches (US FDA/CFSAN Thresh-
old Working Group, 2008). Furthermore, the existing human
data have not been assembled yet for use in risk assessment
approaches. However, the potential does exist for progress in
this regard (see Taylor et al., 2009).
Riskassessmentormodeling approaches havebeen explored
to better and more quantitatively describe the distribution of in-
dividual thresholds (Crevel et al., 2007). The selection of the
ideal statistical model to use will require further research. How-
ever, such approaches have the potential for use to quantita-
tively describe the risks associated with speciﬁc levels of al-
lergenic food residues to segments of the allergic population
(Spanjersberg et al., 2007; Kruizinga et al., 2008). Identiﬁca-
tion of population threshold distributions, coupled with a risk-
based approach, presents advantages to industry, government,
and food-allergic individuals. It would provide the food indus-
try with data needed to generate more accurate and informative
labels. Regulatory agencies would be able to focus regulatory
attention, including recalls, on foods and food ingredients that
pose the greatest risks. Such risk-based approaches would sup-
port more informative and quantitative food labels; in turn, this
may also better protect (and lessen restrictions on) food-allergic
consumers, who appear to be increasingly ignoring qualitative
advisory labels that a product “may contain” an allergen (Heﬂe
et al., 2007).
Thus, advantages exist to using a quantitative risk-based ap-
proach to characterizing thresholds; however, to be effective,
such quantitative modeling approaches must be consistent with
the underlying fundamental biology of the allergic disease pro-
cess. The Key Events Dose-Response Framework provides an
analytical approach for systematically examining the biological
components of the elicitation process. Such an analysis helps
to generate a coherent picture of the various “drivers” of the
allergic response, including drivers that determine the nature
or severity of the response. A systematic review of the biol-
ogy of the elicitation process sheds light on potential sources of
inter- and intra-individual variability, which in turn provides a
more solid scientiﬁc basis for establishing the optimal level of
vigilance for an individual or a population.
APPLICATION OF THE KEY EVENTS APPROACH
TO FOOD ALLERGENS
The focus of this section will be on the use of a key events
analysis to examine dose-response and thresholds for elicitation
of allergic reactions in sensitized individuals. As noted previ-
ously,clinicalevidencedemonstratestheexistenceofthresholds
for elicitation; however, the biological basis of such thresholds
isnotknown.Asystematicexaminationofkeyeventsleadingto
elicitationshouldfacilitatetheassessmentofcurrentknowledge
and identify research most needed to reﬁne the understanding
of dose-response. Future efforts may examine key events in the
development of sensitization; however, much less is known re-
garding that process. Unlike the elicitation response, there are
no substantial collections of data regarding development of sen-
sitization response.734 S. L. TAYLOR ET AL.
Figure 1 Major biological events and factors in the elicitation of a food allergic reaction.
Overview of Key Events
The major biological events in the elicitation of a food al-
lergic reaction are outlined in Fig. 1, along with several factors
or aspects of each event that could, in theory, be quantiﬁed
to reﬂect the “dose” at the event (Taylor and Heﬂe, 2001). To
summarize the pathway of events, elicitation results when a
sensitized individual is re-exposed to a food allergen under con-
ditions that allow binding of an allergen (or its fragments) to
allergen-speciﬁc IgE antibodies that are bound to mast cells and
basophils; if there is sufﬁcient binding, physiologically active
mediatorsarereleasedfromthesecells.Thesemediatorsmaybe
dispersed, or they may interact locally with susceptible tissues.
This interaction underlies the signs and symptoms of allergic
response.
While these events are listed sequentially in Fig. 1, in cer-
tain cases, they may occur almost simultaneously (e.g., signs
and symptoms occur immediately after or simultaneously upon
ingestion). The pathway as presented, however, outlines the
current state of the science with regard to the nature of various
events and their likely relationship to each other.
Analysis of Individual Key Events
Ingestion1
Certainly, the initial dose (i.e., ingested amount of allergenic
protein or peptide) is a key factor in the likelihood of elicita-
tion of a reaction. But the condition of the allergenic proteins
in a food (especially the effects of food processing) can af-
fect their allergenicity. Processing may result in denaturation or
1While ingestion is the typical route of exposure of concern for food allergens, symp-
tomscansometimesalsooccurviacontactoftheseallergenswithskinorwiththerespiratory
mucosa.
degradation of the proteins, chemical modiﬁcations, changes in
solubility, or aggregation with other food components. Any of
these changes can potentially affect the the ability of the protein
or peptide to elicit an allergic reaction. The more severe food
allergens are considered to be quite stable to food processing,
especially heat (Taylor and Lehrer, 1996).
Onceallergenicproteinsorpeptideshavebeeningested,con-
tact with the oral mucosa may lead directly to a reaction. Some
allergens tend to elicit reactions only in the oral cavity (Ortolani
et al., 1988). More speciﬁcally, they elicit reactions by inter-
acting with mucosal mast cells in the mouth and symptoms
start immediately upon consumption. Oral allergy syndrome
(OAS) is a constellation of mild and transitory symptoms local-
ized in and around the mouth. As originally described (Ortolani
et al., 1988), OAS was thought to be associated with inges-
tion of unstable allergens from fruits and vegetables that are
cross-reactive with pollen allergens, the likely original cause of
sensitization. More recently, some foods primarily associated
with OAS (e.g., peach and apple) have been found to also con-
tain more stable allergens (lipid transfer proteins primarily) that
can trigger more severe, systemic reactions (Ballmer-Weber,
2002).
Digestion
Once allergenic proteins or peptides are ingested by a sensi-
tized individual, several factors related to digestion may affect
the dose available to be absorbed, and thus become important
in determining the likelihood of reaction. These include:
• The stability of the proteins to digestive proteases including
pepsin, trypsin, and chymotrypsin,
• The digestive capacity of the host, especially acid produc-
tion in the stomach, which can be affected by physiologicalKEY-EVENTS DOSE REPSONSE FRAMEWORK 735
conditions (e.g. achlorhydria) or pharmacological treatments
(e.g. H2 antihistamines and protein pump inhibitors),
• Interactions with the food matrix.
The food matrix containing the food allergen can affect the
amount (dose) of allergen available for digestion. Some food
allergens,oncefreedfromthematrixandavailablefordigestion,
are considered to be comparatively stable to digestion (Taylor
and Lehrer, 1996). Certainly, some proteolysis may occur but
at a minimum some immunoreactive peptides reach the effector
cells in the intestinal tract and beyond. While there is evidence
thatproteolysiscansometimesgeneratenewallergenicepitopes
(Lehmann et al., 2006), resistance to digestion appears to be a
key attribute of the major food allergens.
Certainhostconditionscanalsoaffectstability.Forexample,
some in vitro evidence indicates that acid suppression therapy
might increase the digestive stability of certain food allergens
(Untersmayr et al., 2003). However, acid suppression therapy
and the serious conditions affecting digestion (e.g., achlorhy-
dria) are more common in adults, which as a subpopulation
tends to be less sensitive to food allergens than young children
and infants.
In summary, the stability of food allergens (i.e., resistance
to proteolysis) is variable across food matrices, across proteins,
andacrossindividuals.Thesefactorswillcertainlyinﬂuencethe
dose available for uptake.
Uptake and Distribution
Uptake of proteins from the digestive tract is inﬂuenced by:
• The existence and location of transporter systems
• The number of transporters and the kinetics of the transport
process, including the afﬁnity of the transport system for the
protein, peptides, or aggregates
• Interactions with blocking antibodies, IgA and IgG, in the
intestinal lumen and mucosa which prevent or slow uptake
• Mucosal integrity, and conditions along the digestive tract
including any pre-existing intestinal injury
• Factors affecting other uptake processes (i.e., those not medi-
ated by transporter systems)
The process of protein uptake into the intestinal mucosa is
not well understood, but could be a pivotal process in deter-
mining the actual dose that is ultimately presented to effector
cells. Speciﬁc transporter systems may exist, or processes such
as pinocytosis may result in mucosal protein uptake. Active up-
take of allergenic proteins, especially those that are digestion-
resistant, may also occur via macrophages, and partial prote-
olysis within such macrophages may result in more reactive
peptides being presented to mast cells. That possibility is spec-
ulative,however,anditisequallylikelythatfoodallergensresist
proteolysis within phagocytic cells, or that phagocytic cells are
not involved.
Intestinal uptake of food allergens may be hindered by the
presence of allergen-speciﬁc IgA antibodies in the intestinal
lumen, which may block (or partially block) uptake of the aller-
genic protein (Mayer, 2003). Stimulation of the production of
allergen-speciﬁc IgA antibodies does not occur in all (or even
most) food-allergic subjects (Barnes et al., 1995). This factor
could potentially be critical to determining the dose absorbed,
and may also explain some of the interindividual variability
in response. Allergen-speciﬁc IgA antibodies may also play a
role in the development of oral tolerance, but that role is as yet
undeﬁned.
Following uptake, the allergen or its immunoreactive break-
down product(s) may directly interact with mucosal mast cells
(asdiscussedbelow).Alternatively,theymayﬁrstbetransported
to other tissues, where they may present to, and ultimately trig-
ger, effector cells, i.e., basophils in the blood or mast cells in
any other tissue of the body.
Cellular Events—Interaction of Allergens with the Immune
System
Onceallergenicproteinsorpeptideshavebeenabsorbedfrom
the digestive tract, they can interact directly with the immune
system, in particular, mast cells of the mucosal tissues. In fact,
thesmallintestineisconsideredaprimarylocaleforinteractions
between mucosal mast cells and food allergens. High numbers
of mast cells and basophils are present in all humans whether
allergic to foods or not. The distinguishing feature of food-
allergic individuals is that their mast cells and basophils (i.e.,
effector cells) are armed with allergen-speciﬁc IgE antibodies
attached to the membrane surfaces. For an allergic reaction to
occur,afoodallergenmustcross-linktheseallergen-speciﬁcIgE
antibodiesonthesurfaceoftheeffectorcells.Thiscross-linking
triggers the release of pre-formed mediators such as histamine,
and may also generate de novo mediators such as leukotrienes
and prostaglandins.
Note that the release of these mediators into the tissues and
bloodstream is dependent upon the cross-linking interaction of
the allergenic protein with the bound IgE antibodies. In order to
achieve the desired spatial geometry required for cross-linking,
the concentration of IgE antibodies attached to the mast cell
membranes must be of sufﬁcient number. But the minimum
(sufﬁcient) number of binding events that must occur in order
to effect mediator release or total mediator release is unknown.
In addition to the number of binding events per cell, there
may be a minimum number of armed mast cells and a minimum
amountofmediatorreleaserequiredinorderforthedownstream
events (interaction of mediators in tissues) to result in signs and
symptoms.Thishasnotbeenclearlydocumentedinfoodallergy,
however. In fact, estimates of the number of allergen-speciﬁc
IgE antibodies bound to mast cells in an allergic reaction do
not exist. Similarly, the amount of stored mediators generated
and released from mast cells and basophils is totally unknown.
These numbers are likely to be variable (across individuals and
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The levels of both total and allergen-speciﬁc serum IgE are
readily measureable. Allergen-speciﬁc IgE levels vary by more
than 100-fold among individuals with food allergies. Quantita-
tively, the level of speciﬁc serum IgE is predictive of allergic
reactivity, and serum cutoff values for IgE levels have been
established to preclude the need for diagnostic oral challenge
tests in patients known to exhibit classical clinical histories for
food-allergicreactions(Sampson,2001).However,thepresence
of serum allergen-speciﬁc IgE can also be demonstrated in in-
dividuals who are not reactive to the speciﬁc food. Thus, the
diagnostic value of serum IgE levels must be coupled to the
allergic history of the patient.
Notably, speciﬁc serum IgE levels in an allergic individual
can be monitored over time to predict with some reliability
when oral tolerance has been achieved and the food-allergic
state has subsided. Total avoidance of an allergen may lead to
a decrease in speciﬁc serum IgE levels. This has been clearly
documented for penicillin where total avoidance is possible
(Celik et al., 2009). The effect of total avoidance is very
difﬁcult to evaluate with food allergens; however, due to the
presence of very low, subclinical levels of the allergenic food
or cross-reactive foods in the diet.
IgG antibodies may also play a role in the elicitation pro-
cess. Allergen-speciﬁc IgG antibodies may block allergen in-
teractions with mast cell-bound or basophil-bound IgE antibod-
ies, thus inhibiting the allergic response (Flicker and Valenta,
2003). Furthermore, allergen-speciﬁc IgG antibodies may acti-
vate inhibitory receptors on mast cells and thus down-regulate
IgE-mediated mast cell activation and the release of mediators
(Saxon et al., 2008). Thus, the production of allergen speciﬁc
IgG antibodies may have the effect of increasing the minimum
dose required to provoke an allergic response (i.e., increasing
the threshold dose).
Lymphocytes also play a role in the inﬂammatory process
in a manner that could affect thresholds. For example, in the
inﬂammatory process, both at the gut level and elsewhere, anti-
gen elicits not only the immediate activation of mast cells and
basophils, but may also stimulate antigen-speciﬁc lymphocytes
to produce cytokines within several hours to amplify the result-
ing allergic inﬂammation (Luccioli et al., 2002; Knight et al.,
2007). This process is itself modiﬁed by regulatory T-cells and
polymorphisms in key receptors, such as the IL-4 receptor.
In summary, multiple factors contribute to determining the
outcome of this key event. Note that some factors may increase
the likelihood of a response (i.e., decrease the minimum
dose required for a response), while others may decrease the
likelihood of response (i.e., increase the threshold dose). The
ultimate response to a given dose is inﬂuenced by a complex
combination of the following (sometimes contradictory) factors
at this key event:
• The number and type of effector cells (mast cells and ba-
sophils) in the body
• Tissue localization of the mast cells
• The number of speciﬁc IgE antibodies on the surface of each
effector cell
• The number/concentration of circulating free IgE molecules
• The number of nonspeciﬁc IgE antibodies on the surface of
each effector cell
• The amount of blocking (IgA and IgG) antibodies
For each effector cell, the magnitude of the response to IgE
binding of target peptides is determined by:
• The types of mediator molecules present in the cell
• The concentrations of the mediator molecules in the cell
• Thepercentofeachcell’sloadofmediatormoleculesreleased
in response to each IgE cross-linking event
• The ability of the cell to generate and release unstored medi-
ators
Cellular Events—Interaction of Mediators with Tissues
The interaction of mediator molecules with various cells and
tissues in the body results in the signs and symptoms of an
allergic reaction. The nature and severity of the reaction are
determined by:
• The site of mediator release
• The catabolism/half-life of the mediator molecules in blood
and tissues
• The ﬁnal concentration of the mediator molecules in the af-
fected tissue
• The number and distribution of receptors for the mediator in
the affected tissue(s)
• The cascade of reactions in response to mediators, including:
• The ability of cells in affected tissue to respond to mediator-
binding events
• The presence and capacity of any homeostatic mechanisms
The site of mediator release is a factor worthy of consid-
eration. Empirical evidence indicates that systemic allergic re-
actions (e.g., onset of hives) progress quickly, suggesting that
mediatorsarerapidlydispersedfromtheoriginalsiteofallergen-
effector interaction to the various tissues where signs and symp-
toms result. Allergic reactions can also occur in the absence
of systemic release of mediators, however. If sufﬁcient levels
of mediators are released within a given tissue, the resulting
response can give the appearance of target organ speciﬁcity.
Accordingly, respiratory symptoms occur more commonly with
inhalation allergens than with food allergens. It is also conceiv-
able that certain target organs, for example the lung may con-
tain populations of cells with lower thresholds for activation,
although this possibility has not been demonstrated.
In addition to the location of mediator-tissue interactions,
variables related to the speciﬁc type of mediator and speciﬁc
receptor polymorphisms may affect the nature or severity of
response. Dozens of different mediators have been identiﬁed
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well as mediators generated in the cascade of events that is ac-
tivated by those cells (Wasserman, 2008; Gandhi et al., 2009).
Giventheverylargenumberofpossiblemediator-receptorcom-
binations, the situation becomes quite complex. Moreover, cer-
tain host conditions or behaviors may also affect the outcome
(e.g., use of ACE inhibitors) (Sabroe and Black, 1997).
Some mediators, such as the key mediator histamine, have
been reasonably well studied.2 Less is known, however, about
other mediators. The speciﬁc nature of the mediator and its
catabolism may be quite critical in determining the mediator
dose required to elicit a response (i.e., critical to determining
an individual’s threshold dose). For example, the half-life of
histamine in serum is quite short owing in part to the action
of histamine-catabolizing enzymes. Again, host conditions or
behaviors,suchastheuseofcertainpharmaceuticals,mayaffect
rates of catabolism and thereby affect threshold doses (Hui and
Taylor, 1985). Recently, the role of the platelet-activating factor
has been examined in anaphylactic reactions, and data suggest
that variability in degradation of this mediator by a circulating
degradative enzyme is critical to the expression and severity of
anaphylaxis (Vadas et al., 2008).
DISCUSSION
Existing human clinical data on elicitation of the food aller-
gic response very clearly show the existence of threshold doses.
But, a hallmark of the food allergic response is the remarkable
variability in threshold doses across sensitized individuals (i.e.,
the relevant population). As noted previously, individual thresh-
olds for elicitation of response to peanut range from 0.5 mg to
8000–10,000 mg (Taylor et al., 2009). Moreover, within a given
individual, the threshold dose can vary over time. There is also
variability in nature and severity of response to a given dose of
a particular food allergen.
But what are the fundamental biological factors that deter-
mine the threshold value? What speciﬁc underlying differences
can explain inter- and intraindividual variability? What is the
biological basis of sensitization, which deﬁnes the relevant pop-
ulation? What is the role of genetic susceptibility, co-existing
disease states, and life-stage in the break-down of tolerance
and development of food allergies? Answers to these questions
can be expected to substantially advance the scientiﬁc basis for
public health decisions used to protect food allergic individuals.
Current decision-making relies heavily on data from human
clinical challenge trials, and such data will likely remain piv-
otal in the practical assessment of population thresholds. The
Key Events Dose-Response Framework, however, promotes an
analytical approach that complements and integrates observa-
tional data from clinical trials and the limited mechanistic data
gleaned from animal studies. More speciﬁcally, this analytical
framework:
2For histamine, human data on its intravenous toxicity exist (Weiss et al., 1932).
• Facilitates systematic consideration of the wide range of fac-
tors that contribute to determining whether a given ingested
dose will, or will not, result in signs or symptoms.
• Provides deeper insight into potential speciﬁc sources of vari-
abilityinresponse.Thisprovidesafoundationformorequan-
titatively characterizing population variability.
• Helps reﬁne the research agenda for food allergy dose-
response assessment.
• Helps to generate new hypotheses and pinpoint critically
needed data.
• Clariﬁes how new data may be used to reﬁne overall under-
standing of dose-response – i.e., illustrates where new pieces
of information will ﬁt into the overall “puzzle.”
The present study was an initial qualitative attempt to exam-
ine key events in the biological pathway underlying elicitation
ofallergicresponsetofoods.Tofurtherthisanalyticalapproach,
futurestudiescouldthoroughlyexaminethestate-of-the-science
and all relevant data regarding these key events for a speciﬁc
food allergen (e.g., peanut). It may also be possible to mine data
that were obtained for other purposes from the literature. For
example, published clinical studies on the efﬁcacy of various
antihistamines may include data from untreated controls that
could be used to better characterize the effector molecule-tissue
interactions described above.
Another future research strategy could involve compilation
of quantitative data on physiological, biochemical, and genetic
differences across human subjects for whom threshold doses
havealreadybeenidentiﬁed(oratleastestimated).Thisstrategy
would require a broad collaboration across clinicians, physiol-
ogists, molecular biologists, statisticians, and others toward de-
veloping a database of biomarkers, genetic polymorphisms, and
other relevant variables for a large population of food-allergic
individuals. Such an effort would begin a process to quantita-
tively reﬁne population threshold distributions; this would be
immediately useful for practical purposes in public health. Per-
haps more importantly, such an effort could be expected to shed
muchlightontheunderlyingbiologyofallergicdisease.Inturn,
this would better inform the risk assessment process, and might
also inform efforts to develop biomarkers of susceptibility. A
compilation of such data would also provide a more robust ba-
sis for evaluating whether test populations are representative of
the full spectrum of allergic individuals.
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